ReviewAdvances in chronic kidney disease2022
Value-Based Care and Kidney Disease: Emergence and Future Opportunities.
Review in Advances in chronic kidney disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Overlap Between Mandatory and Voluntary Value-Based Kidney Care Model Participation and Home Dialysis Use.JAMA health forum · 2026Article
- A qualitative study examining barriers to buprenorphine for pain management in patients with end stage kidney disease undergoing hemodialysis.The journal of pain · 2026Article
- Reimagining kidney value-based care: leveraging data science for dynamic, clinician-level risk prediction.Current opinion in nephrology and hypertension · 2026Review
- Review
- How to Leverage Implementation Science to Achieve Equity in Nephrology Care Delivery.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025Article
- Medicare Advantage Plan and Chronic Kidney Disease Care Management Company Partnerships After the 21st Century Cures Act.Medical care research and review : MCRR · 2025Article
- Rapid and Simultaneous Initiation of Guideline-Directed Kidney Therapies in Patients with CKD and Type 2 Diabetes.Journal of the American Society of Nephrology : JASN · 2025 · on this mapReview
- Learning from the implementation phase of the new French capitation payment model for chronic kidney disease care: a qualitative study.Journal of nephrology · 2025Article
- Population Health Management for Improving Kidney Health Outcomes.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025Article
- Dialysis Preparedness and Access to the Transplant Waitlist: Evidence From a National United States Cohort Study.Kidney international reports · 2025Article
- Patient Voices in Dialysis Care: Sentiment Analysis and Topic Modeling Study of Social Media Discourse.Journal of medical Internet research · 2025Article
- Development, Rasch analysis and validation of the kidney symptom burden questionnaire (KSB-Q).Clinical kidney journal · 2025Article
- Global kidney health priorities-perspectives from the ISN-GKHA.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Review
- Clinical Outcomes of a Novel Multidisciplinary Care Program in Advanced Kidney Disease (PEAK).Kidney international reports · 2024Article
- Current trends in hospice care usage for dialysis patients in the USA.Journal of nephrology · 2023Article
- Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The United States health care system has increasingly embraced value-based programs that reward improved outcomes and lower costs. Health care value, defined as quality per unit cost, was a major goal of the 2010 Patient Protection and Affordable Care Act amid high and rising US health care expenditures. Many early value-based programs were specifically designed for patients with end-stage renal disease (ESRD) and targeted toward dialysis facilities, including the ESRD Prospective Payment System, ESRD Quality Incentive Program, and ESRD Seamless Care Organizations. While a great deal of attention has been paid to these ESRD-focused programs, other value-based programs targeted toward hospitals and health systems may also affect the quality and costs of care for a broader population of patients with kidney disease. Value-based care for kidney disease is increasingly relevant in light of the Advancing American Kidney Health initiative, which introduces new value-based payment models: the mandatory ESRD Treatment Choices Model in 2021 and voluntary Kidney Care Choices Model in 2022. In this review article, we summarize the emergence and impact of value-based programs on the quality and costs of kidney care, with a focus on federal programs. Key opportunities in value-based kidney care include shifting the focus toward chronic kidney disease, enhancing population health management capabilities, improving quality measurement, and leveraging programs to advance health equity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.